Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Perrigo CoPRGO +0.59%54 Cash-to-Debt is 0.12 as of Jun. 2026, which is 20% below its 10-year median of 0.15. GuruFocus rates PRGO with a GF Score™ of 54/100 and a GF Value™ of $23.75 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 984 Drug Manufacturers companies, Perrigo Co ranks worse than 83.33% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Perrigo Co's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.12.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Perrigo Cocouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Perrigo Co's Cash-to-Debt or its related term are showing as below:
PRGO'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.06 Med: 0.15 Max: 0.59
Current: 0.12
During the past 13 years, Perrigo Co's highest Cash to Debt Ratio was 0.59. The lowest was 0.06. And the median was 0.15.
PRGO's Cash-to-Debt is ranked worse than 83.33% of 984
companies
in the Drug Manufacturers industry
Industry Median: 0.96
vs PRGO: 0.12
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Perrigo Co Cash-to-Debt Related Terms
Perrigo Co Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Perrigo Co's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Perrigo Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Perrigo Co Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Perrigo Co's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Perrigo Co's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Perrigo Co (PRGO) has a Cash-to-Debt of 0.12 as of Jun. 2026. This is 20% below median its historical median of 0.15. Over the past decade, Perrigo Co's Cash-to-Debt has ranged from 0.06 to 0.59. According to the industry distribution chart, Perrigo Co ranks #820 out of 984 companies in the Drug Manufacturers industry, placing it in the top 83.3%.
Is Perrigo Co's Cash-to-Debt too high?
Perrigo Co's current Cash-to-Debt of 0.12 is 20% below median its 10-year median of 0.15. Over the past 10 years, this metric has ranged from a low of 0.06 to a high of 0.59. The Drug Manufacturers industry median Cash-to-Debt is 0.96. Perrigo Co's value of 0.12 is 87.5% below this industry median. Based on the distribution chart, Perrigo Co ranks #820 out of 984 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Perrigo Co has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Perrigo Co's Cash-to-Debt compare to ALVO and TRLV?
According to the Drug Manufacturers industry distribution chart, Perrigo Co ranks #820 out of 984 companies for Cash-to-Debt. This places Perrigo Co in the lower half of its industry. The industry median Cash-to-Debt is 0.96. Perrigo Co's value of 0.12 is 87.5% below this benchmark. Historically, Perrigo Co's own Cash-to-Debt has ranged from 0.06 to 0.59 over the past decade. While the company's 10-year median is 0.15 vs. the industry median of 0.96, Perrigo Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 0.96, based on 984 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Perrigo Co's current Cash-to-Debt of 0.12 is 87.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 0.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Perrigo Co's current Cash-to-Debt is 0.12, which is 20% below median its own 10-year median of 0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perrigo Co stock overvalued right now?
Based on GuruFocus' analysis, Perrigo Co (PRGO) is currently considered Possible Value Trap. The stock's GF Value™ is $23.75, compared to a current price of $13.56 — trading 42.9% below its estimated fair value. The current Cash-to-Debt is 0.12, which is 20% below median its 10-year median of 0.15 and 87.5% below the Drug Manufacturers industry median of 0.96. Perrigo Co's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Perrigo Co (PRGO), the current Cash-to-Debt is 0.12 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Perrigo Co (PRGO) Overvalued in 2026?
Based on GuruFocus' analysis, Perrigo Co stock appears to be undervalued.
The current stock price of $13.56 is trading 42.9% below its estimated GF Value™ of $23.75.
GuruFocus considers Perrigo Co to be Possible Value Trap.
Key valuation signals for PRGO:
Cash-to-Debt: 0.12 (20% below median its 10-year median of 0.15)
GF Value™: $23.75 vs. price of $13.56 (42.9% below fair value)
Industry Position: 87.5% below the Drug Manufacturers median (#820 of 984)
No single metric tells the full story. See the PRGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo has divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two-thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
54GF Score
Get the complete analysis for PRGO
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRGO has been successfully added to your 
